BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 31201864)

  • 1. HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges.
    Zeng H; Wang J; Clouse H; Lagrutta A; Sannajust F
    J Pharmacol Toxicol Methods; 2019; 99():106598. PubMed ID: 31201864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolving the Reversed Rate Effect of Calcium Channel Blockers on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and the Impact on In Vitro Cardiac Safety Evaluation.
    Zeng H; Wang J; Clouse H; Lagrutta A; Sannajust F
    Toxicol Sci; 2019 Feb; 167(2):573-580. PubMed ID: 30365015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human-induced pluripotent stem cell-derived cardiomyocytes have limited I
    Zeng H; Wang J; Clouse H; Lagrutta A; Sannajust F
    JRSM Cardiovasc Dis; 2019; 8():2048004019854919. PubMed ID: 31217965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
    Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
    Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
    Huang M; Liao Z; Li X; Yang Z; Fan X; Li Y; Zhao Z; Lang S; Cyganek L; Zhou X; Akin I; Borggrefe M; El-Battrawy I
    Front Pharmacol; 2021; 12():675003. PubMed ID: 34025432
    [No Abstract]   [Full Text] [Related]  

  • 7. Response of human induced pluripotent stem cell-derived cardiomyocytes to several pharmacological agents when intrinsic syncytial pacing is overcome by acute external stimulation.
    Zeng H; Balasubramanian B; Lagrutta A; Sannajust F
    J Pharmacol Toxicol Methods; 2018; 91():18-26. PubMed ID: 29330131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
    Harris K; Aylott M; Cui Y; Louttit JB; McMahon NC; Sridhar A
    Toxicol Sci; 2013 Aug; 134(2):412-26. PubMed ID: 23690542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
    J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical comparison of sodium currents in native cardiac myocytes and human induced pluripotent stem cell-derived cardiomyocytes.
    Goodrow RJ; Desai S; Treat JA; Panama BK; Desai M; Nesterenko VV; Cordeiro JM
    J Pharmacol Toxicol Methods; 2018; 90():19-30. PubMed ID: 29128504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
    Huo J; Wei F; Cai C; Lyn-Cook B; Pang L
    Toxicol Sci; 2019 Feb; 167(2):360-374. PubMed ID: 30247688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts.
    Guo L; Qian JY; Abrams R; Tang HM; Weiser T; Sanders MJ; Kolaja KL
    Cell Physiol Biochem; 2011; 27(5):453-62. PubMed ID: 21691062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of Spontaneous Activity by HCN4 Overexpression in Mouse Embryonic Stem Cell-Derived Cardiomyocytes - A Possible Biological Pacemaker.
    Saito Y; Nakamura K; Yoshida M; Sugiyama H; Ohe T; Kurokawa J; Furukawa T; Takano M; Nagase S; Morita H; Kusano KF; Ito H
    PLoS One; 2015; 10(9):e0138193. PubMed ID: 26384234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch From Fetal to Adult
    Veerman CC; Mengarelli I; Lodder EM; Kosmidis G; Bellin M; Zhang M; Dittmann S; Guan K; Wilde AAM; Schulze-Bahr E; Greber B; Bezzina CR; Verkerk AO
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28739862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
    Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
    PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
    Yamamoto W; Asakura K; Ando H; Taniguchi T; Ojima A; Uda T; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yoshinaga T; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
    PLoS One; 2016; 11(12):e0167348. PubMed ID: 27923051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.